share_log

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Cybin | 6-K：外國發行人報告
美股sec公告 ·  04/16 15:41
Moomoo AI 已提取核心訊息
Cybin Inc., a clinical-stage biopharmaceutical company, announced on April 16, 2024, that the United States Patent and Trademark Office has granted it a U.S. patent (11,958,807) for its CYB003 program, aimed at treating Major Depressive Disorder (MDD). The patent, which is expected to provide exclusivity until at least 2041, covers pharmaceutical compositions within Cybin's proprietary deuterated psilocybin analog program. The company's patent portfolio now includes over 50 granted patents and more than 170 pending applications. Cybin's CEO, Doug Drysdale, highlighted the importance of this patent in protecting their intellectual property and advancing the CYB003 program. The company has also received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for CYB003, which supports a faster regulatory pathway. Cybin plans to begin enrollment for a multinational, multisite Phase 3 program evaluating CYB003 around mid-year 2024. Cybin is focused on developing psychedelic-based therapeutics for mental health conditions and is operational in multiple countries.
Cybin Inc., a clinical-stage biopharmaceutical company, announced on April 16, 2024, that the United States Patent and Trademark Office has granted it a U.S. patent (11,958,807) for its CYB003 program, aimed at treating Major Depressive Disorder (MDD). The patent, which is expected to provide exclusivity until at least 2041, covers pharmaceutical compositions within Cybin's proprietary deuterated psilocybin analog program. The company's patent portfolio now includes over 50 granted patents and more than 170 pending applications. Cybin's CEO, Doug Drysdale, highlighted the importance of this patent in protecting their intellectual property and advancing the CYB003 program. The company has also received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for CYB003, which supports a faster regulatory pathway. Cybin plans to begin enrollment for a multinational, multisite Phase 3 program evaluating CYB003 around mid-year 2024. Cybin is focused on developing psychedelic-based therapeutics for mental health conditions and is operational in multiple countries.
處於臨床階段的生物製藥公司Cybin Inc. 於2024年4月16日宣佈，美國專利商標局已授予其旨在治療重度抑鬱症（MDD）的 CYB003 計劃的美國專利（11,958,807）。該專利預計將至少在2041年之前提供獨家經營權，涵蓋Cybin專有的氘化迷幻藥類似物計劃中的藥物成分。該公司的專利組合現在包括50多項已授予的專利和170多項待處理的申請。Cybin的首席執行官道格·德賴斯代爾強調了該專利在保護其知識產權和推進 CYB003 計劃方面的重要性。該公司還獲得了美國食品藥品監督管理局頒發的 CYB003 突破性療法稱號，該認證支持更快的監管途徑。Cybin計劃在2024年年中左右開始報名一項評估 CYB003 的跨國、多地點的第三階段計劃。Cybin專注於開發基於迷幻藥的心理健康狀況療法，並在多個國家投入運營。
處於臨床階段的生物製藥公司Cybin Inc. 於2024年4月16日宣佈，美國專利商標局已授予其旨在治療重度抑鬱症（MDD）的 CYB003 計劃的美國專利（11,958,807）。該專利預計將至少在2041年之前提供獨家經營權，涵蓋Cybin專有的氘化迷幻藥類似物計劃中的藥物成分。該公司的專利組合現在包括50多項已授予的專利和170多項待處理的申請。Cybin的首席執行官道格·德賴斯代爾強調了該專利在保護其知識產權和推進 CYB003 計劃方面的重要性。該公司還獲得了美國食品藥品監督管理局頒發的 CYB003 突破性療法稱號，該認證支持更快的監管途徑。Cybin計劃在2024年年中左右開始報名一項評估 CYB003 的跨國、多地點的第三階段計劃。Cybin專注於開發基於迷幻藥的心理健康狀況療法，並在多個國家投入運營。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息